PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
30022576-9	2019	Finally, we found that systemic administration of the CRMP2 inhibitor, lacosamide, attenuates alcohol priming-induced reinstatement of CPP.	Lacosamide	71-81	dihydropyrimidinase like 2	Homo sapiens	54-59
31377562-3	2019	Therefore, in this study, we investigated the effect of lacosamide, an antiepileptic drug and a known CRMP-2 inhibitor, which binds to CRMP-2 and inhibits the formation of microtubule assembly, on ethanol-induced conditioned place preference (CPP) in mice.	Lacosamide	56-66	dihydropyrimidinase-like 2	Mus musculus	102-108
31377562-3	2019	Therefore, in this study, we investigated the effect of lacosamide, an antiepileptic drug and a known CRMP-2 inhibitor, which binds to CRMP-2 and inhibits the formation of microtubule assembly, on ethanol-induced conditioned place preference (CPP) in mice.	Lacosamide	56-66	dihydropyrimidinase-like 2	Mus musculus	135-141
31377562-9	2019	Lacosamide significantly reduced the expression of ethanol-induced CPP and alleviated the levels of hippocampal CRMP-2 but aggravated withdrawal-associated anxiety and depression in mice.	Lacosamide	0-10	dihydropyrimidinase-like 2	Mus musculus	112-118
31377562-10	2019	CONCLUSION: The present study demonstrated the beneficial effect of lacosamide in attenuation of expression of ethanol induced conditioned place preference via reduction of hippocampal CRMP-2 level.	Lacosamide	68-78	dihydropyrimidinase-like 2	Mus musculus	185-191
31116960-0	2019	Enhancing effect of aerobic training on learning and memory performance in rats after long-term treatment with Lacosamide via BDNF-TrkB signaling pathway.	Lacosamide	111-121	brain-derived neurotrophic factor	Rattus norvegicus	126-130
31116960-0	2019	Enhancing effect of aerobic training on learning and memory performance in rats after long-term treatment with Lacosamide via BDNF-TrkB signaling pathway.	Lacosamide	111-121	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	131-135
31116960-11	2019	Our results show that aerobic training increases the hippocampal BDNF/TrkB expression suggesting a role in preventing the negative effect of Lacosamide on cognitive functions in rats.	Lacosamide	141-151	brain-derived neurotrophic factor	Rattus norvegicus	65-69
31116960-11	2019	Our results show that aerobic training increases the hippocampal BDNF/TrkB expression suggesting a role in preventing the negative effect of Lacosamide on cognitive functions in rats.	Lacosamide	141-151	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	70-74
30118739-6	2018	Treatment with PGB or LCM restored the sciatic nerve content of the depleted total antioxidant capacity (TAC) and nerve growth factor (NGF), and lessened the elevated contents of nuclear factor kappa B p65 (NF-kB p65), tumor necrosis factor-alpha (TNF-alpha), and active caspase-3.	Lacosamide	22-25	caspase 3	Rattus norvegicus	271-280
32269836-0	2019	Modulation of CRMP2 via (S)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease.	Lacosamide	24-38	dihydropyrimidinase-like 2	Mus musculus	14-19
32269836-2	2019	Here we test the therapeutic efficacy of modulating collapsin response mediator protein 2 (CRMP2) activity via S-N-benzy-2-acetamido-3-methoxypropionamide ((S)-Lacosamide) in a mouse model of CLN6-Batten disease.	Lacosamide	156-170	dihydropyrimidinase-like 2	Mus musculus	52-89
32269836-2	2019	Here we test the therapeutic efficacy of modulating collapsin response mediator protein 2 (CRMP2) activity via S-N-benzy-2-acetamido-3-methoxypropionamide ((S)-Lacosamide) in a mouse model of CLN6-Batten disease.	Lacosamide	156-170	dihydropyrimidinase-like 2	Mus musculus	91-96
32269836-3	2019	Promisingly, mouse neuronal cultures as well as Cln6 patient fibroblasts treated with varying concentrations of (S)-Lacosamide showed positive restoration of lysosomal associated deficits.	Lacosamide	112-126	ceroid-lipofuscinosis, neuronal 6	Mus musculus	48-52
30738136-8	2019	Our results suggest that the protection against neuronal loss in specific limbic regions and overexpressed BDNF in the mossy fibers resulting from the repeated treatment with Ago and LCM, respectively, during SE is not a prerequisite for alleviation of epileptogenesis and development of epilepsy.	Lacosamide	183-186	brain-derived neurotrophic factor	Rattus norvegicus	107-111
30649227-0	2019	Lacosamide in patients with Nav1.7 mutations-related small fibre neuropathy: a randomized controlled trial.	Lacosamide	0-10	sodium voltage-gated channel alpha subunit 9	Homo sapiens	28-34
30649227-3	2019	The anticonvulsant lacosamide acts on Nav1.3, Nav1.7, and Nav1.8.	Lacosamide	19-29	sodium voltage-gated channel alpha subunit 3	Homo sapiens	38-44
30649227-3	2019	The anticonvulsant lacosamide acts on Nav1.3, Nav1.7, and Nav1.8.	Lacosamide	19-29	sodium voltage-gated channel alpha subunit 9	Homo sapiens	46-52
30649227-3	2019	The anticonvulsant lacosamide acts on Nav1.3, Nav1.7, and Nav1.8.	Lacosamide	19-29	sodium voltage-gated channel alpha subunit 10	Homo sapiens	58-64
30649227-4	2019	The aim of this study was to evaluate the efficacy, safety, and tolerability of lacosamide as a potential treatment for pain in Nav1.7-related small fibre neuropathy.	Lacosamide	80-90	sodium voltage-gated channel alpha subunit 9	Homo sapiens	128-134
30649227-18	2019	Lacosamide was well tolerated and safe, suggesting that it can be used for pain treatment in Nav1.7-related small fibre neuropathy.	Lacosamide	0-10	sodium voltage-gated channel alpha subunit 9	Homo sapiens	93-99
30169428-0	2018	Lacosamide modulates collapsin response mediator protein 2 and inhibits mossy fiber sprouting after kainic acid-induced status epilepticus.	Lacosamide	0-10	dihydropyrimidinase like 2	Homo sapiens	21-58
30169428-5	2018	Lacosamide (LCM), a novel antiepileptic drug, was recently found to inhibit the CRMP2-mediated neurite outgrowth.	Lacosamide	0-10	dihydropyrimidinase like 2	Homo sapiens	80-85
30169428-5	2018	Lacosamide (LCM), a novel antiepileptic drug, was recently found to inhibit the CRMP2-mediated neurite outgrowth.	Lacosamide	12-15	dihydropyrimidinase like 2	Homo sapiens	80-85
30169428-11	2018	CRMP2 is possibly involved in the mechanism by which LCM suppresses MFS and is expected to be a new therapeutic target for treating epileptogenesis.	Lacosamide	53-56	dihydropyrimidinase like 2	Homo sapiens	0-5
30118739-6	2018	Treatment with PGB or LCM restored the sciatic nerve content of the depleted total antioxidant capacity (TAC) and nerve growth factor (NGF), and lessened the elevated contents of nuclear factor kappa B p65 (NF-kB p65), tumor necrosis factor-alpha (TNF-alpha), and active caspase-3.	Lacosamide	22-25	tumor necrosis factor	Rattus norvegicus	219-246
30118739-6	2018	Treatment with PGB or LCM restored the sciatic nerve content of the depleted total antioxidant capacity (TAC) and nerve growth factor (NGF), and lessened the elevated contents of nuclear factor kappa B p65 (NF-kB p65), tumor necrosis factor-alpha (TNF-alpha), and active caspase-3.	Lacosamide	22-25	tumor necrosis factor	Rattus norvegicus	248-257
30118739-8	2018	Therefore, the current study demonstrated a pivotal role for LCM in the management of PTX-induced peripheral neuropathy similar to PGB, but without motor adverse effects via the inhibition of oxidative stress, inflammation and apoptosis, as well as IL-6/JAK/STAT pathway and Notch1 receptor over-expression.	Lacosamide	61-64	notch receptor 1	Rattus norvegicus	275-281
30525123-7	2018	We additionally measured HDAC1 activity in the presence of lacosamide.	Lacosamide	59-69	histone deacetylase 1	Homo sapiens	25-30
28660485-9	2018	The CRMP2 phosphorylation inhibitor (S)-lacosamide reduces, in a concentration-dependent manner, glioblastoma cell proliferation and induced apoptosis in all three GBM cell lines tested.	Lacosamide	36-50	dihydropyrimidinase like 2	Homo sapiens	4-9
30361185-0	2018	Lacosamide for SCN2A-related intractable neonatal and infantile seizures.	Lacosamide	0-10	sodium voltage-gated channel alpha subunit 2	Homo sapiens	15-20
29605232-0	2018	Chronic treatment with the new anticonvulsant drug lacosamide impairs learning and memory processes in rats: A possible role of BDNF/TrkB ligand receptor system.	Lacosamide	51-61	brain-derived neurotrophic factor	Rattus norvegicus	128-132
29605232-0	2018	Chronic treatment with the new anticonvulsant drug lacosamide impairs learning and memory processes in rats: A possible role of BDNF/TrkB ligand receptor system.	Lacosamide	51-61	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	133-137
29605232-2	2018	The objective of the present study was to investigate the effects of lacosamide (LCM) on learning and memory processes in rats, on the serum level of brain-derived neurotrophic factor (BDNF) and BDNF/TrkB ligand receptor system expression in the hippocampal formation.	Lacosamide	69-79	brain-derived neurotrophic factor	Rattus norvegicus	185-189
29605232-2	2018	The objective of the present study was to investigate the effects of lacosamide (LCM) on learning and memory processes in rats, on the serum level of brain-derived neurotrophic factor (BDNF) and BDNF/TrkB ligand receptor system expression in the hippocampal formation.	Lacosamide	69-79	brain-derived neurotrophic factor	Rattus norvegicus	195-199
29605232-9	2018	Lacosamide induced a dose-dependent reduction of the hippocampal expression of BDNF and its receptor TrkB.	Lacosamide	0-10	brain-derived neurotrophic factor	Rattus norvegicus	79-83
29605232-9	2018	Lacosamide induced a dose-dependent reduction of the hippocampal expression of BDNF and its receptor TrkB.	Lacosamide	0-10	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	101-105
28809766-10	2017	Prevention of CRMP2 phosphorylation with (S)-lacosamide resulted in normalization of channel current densities, excitability, as well as of hyperalgesia following CRISPR/Cas9 truncation of neurofibromin.	Lacosamide	41-55	neurofibromin 1	Homo sapiens	189-202
29335280-3	2018	Analysis of NaV1.7 complexes affinity-purified under native conditions by mass spectrometry revealed 267 proteins associated with Nav1.7 in vivo The sodium channel beta3 (Scn3b), rather than the beta1 subunit, complexes with Nav1.7, and we demonstrate an interaction between collapsing-response mediator protein (Crmp2) and Nav1.7, through which the analgesic drug lacosamide regulates Nav1.7 current density.	Lacosamide	365-375	calcium channel, voltage-dependent, beta 3 subunit	Mus musculus	164-169
29335280-3	2018	Analysis of NaV1.7 complexes affinity-purified under native conditions by mass spectrometry revealed 267 proteins associated with Nav1.7 in vivo The sodium channel beta3 (Scn3b), rather than the beta1 subunit, complexes with Nav1.7, and we demonstrate an interaction between collapsing-response mediator protein (Crmp2) and Nav1.7, through which the analgesic drug lacosamide regulates Nav1.7 current density.	Lacosamide	365-375	sodium channel, voltage-gated, type III, beta	Mus musculus	171-176
28809766-0	2017	CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide.	Lacosamide	134-148	neurofibromin 1	Homo sapiens	23-26
29466837-8	2018	The antiseizure medications phenytoin and lacosamide selectively blocked slowly inactivating over transient current in wild-type and mutant Nav1.3 channels.	Lacosamide	42-52	sodium voltage-gated channel alpha subunit 3	Homo sapiens	140-146
28881259-0	2017	Sodium channel blockers in KCNQ2-encephalopathy: Lacosamide as a new treatment option.	Lacosamide	49-59	potassium voltage-gated channel subfamily Q member 2	Homo sapiens	27-32
28809766-0	2017	CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide.	Lacosamide	134-148	dihydropyrimidinase like 2	Homo sapiens	43-48
28809766-0	2017	CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide.	Lacosamide	134-148	neurofibromin 1	Homo sapiens	76-100
28809766-10	2017	Prevention of CRMP2 phosphorylation with (S)-lacosamide resulted in normalization of channel current densities, excitability, as well as of hyperalgesia following CRISPR/Cas9 truncation of neurofibromin.	Lacosamide	41-55	dihydropyrimidinase like 2	Homo sapiens	14-19
28587680-11	2017	The exposure of glioma cells to brivaracetam and lacosamide resulted in the modulation of several microRNAs; particularly, the effect of miR-195-5p modulation seemed to affect cell cycle, while miR-107 seemed to be implicated in the inhibition of cells migration.	Lacosamide	49-59	microRNA 195	Homo sapiens	137-144
28139023-5	2017	RESULTS: In normal skin, the averaged postdose LEP peak-to-peak-(PtP)-amplitudes were reduced by pregabalin (-2.68 muV; 95% confidence interval (CI) -4.16, 1.19) and duloxetine (-1.73 muV; 95% CI -3.21, -0.26) but not by lacosamide and celecoxib vs. placebo.	Lacosamide	221-231	leptin	Homo sapiens	47-50
28139023-7	2017	LEP PtP amplitudes on capsaicin-irritated skin, reflecting peripheral/spinal sensitization, as in neuropathic pain, were reduced by pregabalin (-3.78 muV; 95% CI -5.31, -2.25) and duloxetine (-2.32 muV; 95% CI -3.82, -0.82) but not by celecoxib or lacosamide vs. placebo, which was in agreement with known clinical profiles.	Lacosamide	248-258	leptin	Homo sapiens	0-3
28587680-11	2017	The exposure of glioma cells to brivaracetam and lacosamide resulted in the modulation of several microRNAs; particularly, the effect of miR-195-5p modulation seemed to affect cell cycle, while miR-107 seemed to be implicated in the inhibition of cells migration.	Lacosamide	49-59	microRNA 107	Homo sapiens	194-201
28597842-3	2017	Lacosamide was initiated at 100 mg/day (50 mg bid) and uptitrated over a 12-week period to 200, 300 or 400 mg/day, based on safety and seizure control.	Lacosamide	0-10	BH3 interacting domain death agonist	Homo sapiens	46-49
28271640-1	2017	BACKGROUND AND PURPOSE: Lacosamide (LCM) is an antiepileptic drug that enhances the slow inactivation of sodium channels and modulates collapsin response mediator protein-2.	Lacosamide	24-34	dihydropyrimidinase-like 2	Rattus norvegicus	135-172
28119481-0	2017	Lacosamide Inhibition of Nav1.7 Voltage-Gated Sodium Channels: Slow Binding to Fast-Inactivated States.	Lacosamide	0-10	sodium voltage-gated channel alpha subunit 9	Homo sapiens	25-31
28271640-1	2017	BACKGROUND AND PURPOSE: Lacosamide (LCM) is an antiepileptic drug that enhances the slow inactivation of sodium channels and modulates collapsin response mediator protein-2.	Lacosamide	36-39	dihydropyrimidinase-like 2	Rattus norvegicus	135-172
26952865-5	2017	Finally, we show that systemic administration of the CRMP-2 inhibitor lacosamide, or knockdown of CRMP-2 in the NAc decreases excessive alcohol intake.	Lacosamide	70-80	dihydropyrimidinase like 2	Homo sapiens	53-59
26729049-0	2016	Lacosamide inhibits calcitonin gene-related peptide production and release at trigeminal level in the rat.	Lacosamide	0-10	calcitonin-related polypeptide alpha	Rattus norvegicus	20-51
27209305-0	2016	Increases of Catalase and Glutathione Peroxidase Expressions by Lacosamide Pretreatment Contributes to Neuroprotection Against Experimentally Induced Transient Cerebral Ischemia.	Lacosamide	64-74	catalase	Homo sapiens	13-21
27423106-12	2016	Furthermore, antiseizure efficacy appeared to be maintained, suggesting that deinduction of CYP enzymes following a switch from CBZ to lacosamide as adjunctive therapy to LEV is feasible within 8weeks and is associated with normalization of serum parameters.	Lacosamide	135-145	peptidylprolyl isomerase G	Homo sapiens	92-95
27209305-5	2016	Lacosamide pre-treatment increased expressions of CAT and GPX, not SOD1 and 2, in the CA1 pyramidal neurons compared with controls, and their expressions induced by lacosamide pre-treatment were maintained after transient cerebral ischemia.	Lacosamide	0-10	catalase	Homo sapiens	50-53
27209305-5	2016	Lacosamide pre-treatment increased expressions of CAT and GPX, not SOD1 and 2, in the CA1 pyramidal neurons compared with controls, and their expressions induced by lacosamide pre-treatment were maintained after transient cerebral ischemia.	Lacosamide	165-175	catalase	Homo sapiens	50-53
27209305-6	2016	In brief, pre-treatment with lacosamide protected hippocampal CA1 pyramidal neurons from ischemic damage induced by transient global cerebral ischemia, and the lacosamide-mediated neuroprotection may be closely related to increases of CAT and GPX expressions by lacosamide pre-treatment.	Lacosamide	29-39	catalase	Homo sapiens	235-238
27209305-6	2016	In brief, pre-treatment with lacosamide protected hippocampal CA1 pyramidal neurons from ischemic damage induced by transient global cerebral ischemia, and the lacosamide-mediated neuroprotection may be closely related to increases of CAT and GPX expressions by lacosamide pre-treatment.	Lacosamide	160-170	catalase	Homo sapiens	235-238
27209305-6	2016	In brief, pre-treatment with lacosamide protected hippocampal CA1 pyramidal neurons from ischemic damage induced by transient global cerebral ischemia, and the lacosamide-mediated neuroprotection may be closely related to increases of CAT and GPX expressions by lacosamide pre-treatment.	Lacosamide	160-170	catalase	Homo sapiens	235-238
26729049-7	2016	RESULTS: We found that: (1) lacosamide inhibits CGRP release from brainstem explants under basal conditions as well as after stimulation by 56 mM KCl, 10 muM veratridine or 1 muM capsaicin; and (2) the i.p.	Lacosamide	28-38	calcitonin-related polypeptide alpha	Rattus norvegicus	48-52
26729049-8	2016	administration of nitroglycerine produces an increase in CGRP levels in the brainstem and trigeminal ganglia, which is inhibited by a pre-treatment with lacosamide.	Lacosamide	153-163	calcitonin-related polypeptide alpha	Rattus norvegicus	57-61
26967696-0	2016	(S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology.	Lacosamide	0-14	dihydropyrimidinase like 2	Homo sapiens	29-34
26967696-5	2016	A search for small molecules that could recapitulate uncoupling of the CaV2.2-CRMP2 interaction identified (S)-lacosamide [(S)-LCM], the inactive enantiomer of the Food and Drug Administration-approved antiepileptic drug (R)-lacosamide [(R)-LCM, Vimpat].	Lacosamide	107-121	dihydropyrimidinase like 2	Homo sapiens	78-83
26606192-1	2015	PURPOSE: To evaluate the efficacy, safety, and tolerability of lacosamide in adults with LGS in the clinical setting.	Lacosamide	63-73	lengsin, lens protein with glutamine synthetase domain	Homo sapiens	89-92
27917413-7	2016	Screening protocols surprisingly revealed that (S)-Lacosamide ((S)-LCM), an inactive analog of the clinically-approved small molecule anti-epileptic drug (R)-Lacosamide (Vimpat ), inhibited CRMP2 phosphorylation by cyclin dependent kinase 5 (Cdk5) in rat TG slices and decreased depolarization-evoked Ca2+ influx in TG cells in culture.	Lacosamide	47-61	dihydropyrimidinase-like 2	Rattus norvegicus	190-195
27917413-7	2016	Screening protocols surprisingly revealed that (S)-Lacosamide ((S)-LCM), an inactive analog of the clinically-approved small molecule anti-epileptic drug (R)-Lacosamide (Vimpat ), inhibited CRMP2 phosphorylation by cyclin dependent kinase 5 (Cdk5) in rat TG slices and decreased depolarization-evoked Ca2+ influx in TG cells in culture.	Lacosamide	47-61	cyclin-dependent kinase 5	Rattus norvegicus	215-240
27917413-7	2016	Screening protocols surprisingly revealed that (S)-Lacosamide ((S)-LCM), an inactive analog of the clinically-approved small molecule anti-epileptic drug (R)-Lacosamide (Vimpat ), inhibited CRMP2 phosphorylation by cyclin dependent kinase 5 (Cdk5) in rat TG slices and decreased depolarization-evoked Ca2+ influx in TG cells in culture.	Lacosamide	47-61	cyclin-dependent kinase 5	Rattus norvegicus	242-246
27917413-7	2016	Screening protocols surprisingly revealed that (S)-Lacosamide ((S)-LCM), an inactive analog of the clinically-approved small molecule anti-epileptic drug (R)-Lacosamide (Vimpat ), inhibited CRMP2 phosphorylation by cyclin dependent kinase 5 (Cdk5) in rat TG slices and decreased depolarization-evoked Ca2+ influx in TG cells in culture.	Lacosamide	170-176	dihydropyrimidinase-like 2	Rattus norvegicus	190-195
25846820-0	2016	(S)-Lacosamide Binding to Collapsin Response Mediator Protein 2 (CRMP2) Regulates CaV2.2 Activity by Subverting Its Phosphorylation by Cdk5.	Lacosamide	0-14	dihydropyrimidinase like 2	Homo sapiens	26-63
25846820-0	2016	(S)-Lacosamide Binding to Collapsin Response Mediator Protein 2 (CRMP2) Regulates CaV2.2 Activity by Subverting Its Phosphorylation by Cdk5.	Lacosamide	0-14	dihydropyrimidinase like 2	Homo sapiens	65-70
25846820-0	2016	(S)-Lacosamide Binding to Collapsin Response Mediator Protein 2 (CRMP2) Regulates CaV2.2 Activity by Subverting Its Phosphorylation by Cdk5.	Lacosamide	0-14	calcium voltage-gated channel subunit alpha1 B	Homo sapiens	82-88
25846820-0	2016	(S)-Lacosamide Binding to Collapsin Response Mediator Protein 2 (CRMP2) Regulates CaV2.2 Activity by Subverting Its Phosphorylation by Cdk5.	Lacosamide	0-14	cyclin dependent kinase 5	Homo sapiens	135-139
27363506-0	2016	Efficacy, safety, and tolerability of lacosamide in patients with gain-of-function Nav1.7 mutation-related small fiber neuropathy: study protocol of a randomized controlled trial-the LENSS study.	Lacosamide	38-48	sodium voltage-gated channel alpha subunit 9	Homo sapiens	83-89
27363506-4	2016	Lacosamide is an anticonvulsant, which blocks Nav1.3, Nav1.7, and Nav1.8, and stabilizes channels in the slow-inactivation state.	Lacosamide	0-10	sodium voltage-gated channel alpha subunit 3	Homo sapiens	46-52
27363506-4	2016	Lacosamide is an anticonvulsant, which blocks Nav1.3, Nav1.7, and Nav1.8, and stabilizes channels in the slow-inactivation state.	Lacosamide	0-10	sodium voltage-gated channel alpha subunit 9	Homo sapiens	54-60
27363506-4	2016	Lacosamide is an anticonvulsant, which blocks Nav1.3, Nav1.7, and Nav1.8, and stabilizes channels in the slow-inactivation state.	Lacosamide	0-10	sodium voltage-gated channel alpha subunit 10	Homo sapiens	66-72
27363506-5	2016	Since multiple Nav1.7 mutations in small fiber neuropathy showed impaired slow-inactivation, lacosamide might be effective.	Lacosamide	93-103	sodium voltage-gated channel alpha subunit 9	Homo sapiens	15-21
27363506-16	2016	DISCUSSION: This is the first study that will be evaluating the efficacy, safety, and tolerability of lacosamide versus placebo in patients with SCN9A-associated small fiber neuropathy.	Lacosamide	102-112	sodium voltage-gated channel alpha subunit 9	Homo sapiens	145-150
27363506-17	2016	The findings may increase the knowledge on lacosamide as a potential treatment option in patients with painful neuropathies, considering the central role of Nav1.7 in pain.	Lacosamide	43-53	sodium voltage-gated channel alpha subunit 9	Homo sapiens	157-163
26668588-3	2015	Neuronal Nuclei immunohistochemistry demonstrated that pre- and post-surgical treatment (5 min ischemia) with 25 mg/kg lacosamide protected CA1 pyramidal neurons in the lacosamide-treated-ischemia-operated group from ischemic injury 5 days post-ischemia, as compared with gerbils in the vehicle-treated-ischemia-operated group.	Lacosamide	119-129	carbonic anhydrase 1	Homo sapiens	140-143
26668588-3	2015	Neuronal Nuclei immunohistochemistry demonstrated that pre- and post-surgical treatment (5 min ischemia) with 25 mg/kg lacosamide protected CA1 pyramidal neurons in the lacosamide-treated-ischemia-operated group from ischemic injury 5 days post-ischemia, as compared with gerbils in the vehicle-treated-ischemia-operated group.	Lacosamide	169-179	carbonic anhydrase 1	Homo sapiens	140-143
26668588-4	2015	Furthermore, treatment with 25 mg/kg lacosamide markedly attenuated the activation of astrocytes and microglia in the ischemic CA1 region at 5 days post-ischemia.	Lacosamide	37-47	carbonic anhydrase 1	Homo sapiens	127-130
26668588-6	2015	In addition, the neuroprotective effects of lacosamide may be associated with decreased activation of glial cells in the ischemic CA1 region.	Lacosamide	44-54	carbonic anhydrase 1	Homo sapiens	130-133
26606192-8	2015	RESULTS: We found that lacosamide only improves the seizure rate in three out of 19 patients with LGS, in two of them by more than 50%.	Lacosamide	23-33	lengsin, lens protein with glutamine synthetase domain	Homo sapiens	98-101
25916937-2	2015	The aim of this study is to investigate the potential anti-inflammatory and lipid-peroxidation inhibiting activities of lacosamide by measuring tumour necrotizing factor-alpha (TNF-alpha), C-reactive protein (CRP), malondialdehyde (MDA) and white blood cells (WBC) using electroneuromyography (ENMG) in rats with sepsis-induced critical illness neuropathy (SICIN).	Lacosamide	120-130	tumor necrosis factor	Rattus norvegicus	177-186
25916937-7	2015	When CLP, CLP+lacosamide 20 mg/kg and CLP+lacosamide 40 mg/kg groups were compared, plasma levels of TNF-alpha and MDA were significantly higher in the untreated CLP group (F = 12.74, P < 0.0001), (F = 19.43, P < 0.05).	Lacosamide	42-52	tumor necrosis factor	Rattus norvegicus	101-110
25916937-8	2015	In the CLP+lacosamide 40 mg/kg group, CRP levels were significantly lower only compared to the CLP group (P < 0.001).	Lacosamide	11-21	C-reactive protein	Rattus norvegicus	38-41
24563546-11	2014	Unexpectedly, lacosamide elicited a time-dependent block of persistent hNav1.5-CW Na(+) currents with an IC50 of 242 +- 19 microM (n = 5).	Lacosamide	14-24	sodium voltage-gated channel alpha subunit 5	Homo sapiens	71-78
25931268-0	2015	Lacosamide reduces HDAC levels in the brain and improves memory: Potential for treatment of Alzheimer"s disease.	Lacosamide	0-10	histone deacetylase 9	Homo sapiens	19-23
25931268-1	2015	Lacosamide, a histone deacetylase (HDAC) inhibitor, has been approved for the treatment of epilepsy.	Lacosamide	0-10	histone deacetylase 9	Homo sapiens	14-33
25931268-1	2015	Lacosamide, a histone deacetylase (HDAC) inhibitor, has been approved for the treatment of epilepsy.	Lacosamide	0-10	histone deacetylase 9	Homo sapiens	35-39
25931268-3	2015	The present investigation was designed to evaluate the effect of lacosamide on memory and brain HDAC levels.	Lacosamide	65-75	histone deacetylase 9	Homo sapiens	96-100
25931268-10	2015	These results suggest that lacosamide at a 30mg/kg dose improves disrupted memory, possibly by inhibiting HDAC, and could be used to treat amnesic symptoms of Alzheimer"s disease.	Lacosamide	27-37	histone deacetylase 9	Homo sapiens	106-110
25104922-0	2014	The functionalized amino acid (S)-Lacosamide subverts CRMP2-mediated tubulin polymerization to prevent constitutive and activity-dependent increase in neurite outgrowth.	Lacosamide	30-44	dihydropyrimidinase like 2	Homo sapiens	54-59
25104922-6	2014	This led to the identification of (S)-lacosamide ((S)-LCM), a stereoisomer of the clinically used antiepileptic drug (R)-LCM (Vimpat ), as a novel tool for preferentially targeting CRMP2-mediated neurite outgrowth.	Lacosamide	34-48	dihydropyrimidinase like 2	Homo sapiens	181-186
25104922-6	2014	This led to the identification of (S)-lacosamide ((S)-LCM), a stereoisomer of the clinically used antiepileptic drug (R)-LCM (Vimpat ), as a novel tool for preferentially targeting CRMP2-mediated neurite outgrowth.	Lacosamide	126-132	dihydropyrimidinase like 2	Homo sapiens	181-186
24567279-1	2014	BACKGROUND: The antiepileptic drug lacosamide has a low potential for drug-drug interactions, but is a substrate and moderate inhibitor of the cytochrome P450 (CYP) enzyme CYP2C19.	Lacosamide	35-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-158
24567279-1	2014	BACKGROUND: The antiepileptic drug lacosamide has a low potential for drug-drug interactions, but is a substrate and moderate inhibitor of the cytochrome P450 (CYP) enzyme CYP2C19.	Lacosamide	35-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	160-163
24567279-1	2014	BACKGROUND: The antiepileptic drug lacosamide has a low potential for drug-drug interactions, but is a substrate and moderate inhibitor of the cytochrome P450 (CYP) enzyme CYP2C19.	Lacosamide	35-45	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	172-179
24634110-1	2014	BACKGROUND: Recent data suggest that P-glycoprotein may be involved in cellular transport of lacosamide.	Lacosamide	93-103	ATP binding cassette subfamily B member 1	Homo sapiens	37-51
24944082-0	2015	Specific binding of lacosamide to collapsin response mediator protein 2 (CRMP2) and direct impairment of its canonical function: implications for the therapeutic potential of lacosamide.	Lacosamide	20-30	dihydropyrimidinase like 2	Homo sapiens	34-71
24944082-0	2015	Specific binding of lacosamide to collapsin response mediator protein 2 (CRMP2) and direct impairment of its canonical function: implications for the therapeutic potential of lacosamide.	Lacosamide	20-30	dihydropyrimidinase like 2	Homo sapiens	73-78
24944082-1	2015	The novel antiepileptic drug lacosamide (LCM; SPM927, Vimpat ) has been heralded as having a dual-mode of action through interactions with both the voltage-gated sodium channel and the neurite outgrowth-promoting collapsin response mediator protein 2 (CRMP2).	Lacosamide	29-39	dihydropyrimidinase like 2	Homo sapiens	213-250
24944082-1	2015	The novel antiepileptic drug lacosamide (LCM; SPM927, Vimpat ) has been heralded as having a dual-mode of action through interactions with both the voltage-gated sodium channel and the neurite outgrowth-promoting collapsin response mediator protein 2 (CRMP2).	Lacosamide	29-39	dihydropyrimidinase like 2	Homo sapiens	252-257
24944082-1	2015	The novel antiepileptic drug lacosamide (LCM; SPM927, Vimpat ) has been heralded as having a dual-mode of action through interactions with both the voltage-gated sodium channel and the neurite outgrowth-promoting collapsin response mediator protein 2 (CRMP2).	Lacosamide	41-44	dihydropyrimidinase like 2	Homo sapiens	213-250
24944082-1	2015	The novel antiepileptic drug lacosamide (LCM; SPM927, Vimpat ) has been heralded as having a dual-mode of action through interactions with both the voltage-gated sodium channel and the neurite outgrowth-promoting collapsin response mediator protein 2 (CRMP2).	Lacosamide	41-44	dihydropyrimidinase like 2	Homo sapiens	252-257
24944082-3	2015	While the role of CRMP2 in epilepsy has not been well studied, given the proposed involvement of circuit reorganization in epileptogenesis, the ability of lacosamide to alter CRMP2 function may prove disease modifying.	Lacosamide	155-165	dihydropyrimidinase like 2	Homo sapiens	175-180
24944082-4	2015	Recently, however, the validity of lacosamide"s interaction with CRMP2 has come under scrutiny.	Lacosamide	35-45	dihydropyrimidinase like 2	Homo sapiens	65-70
24944082-5	2015	In this review, we address the contradictory reports concerning the binding of lacosamide to CRMP2 as well as the ability of lacosamide to directly impact CRMP2 function.	Lacosamide	79-89	dihydropyrimidinase like 2	Homo sapiens	93-98
24944082-5	2015	In this review, we address the contradictory reports concerning the binding of lacosamide to CRMP2 as well as the ability of lacosamide to directly impact CRMP2 function.	Lacosamide	125-135	dihydropyrimidinase like 2	Homo sapiens	155-160
25534720-3	2015	With the two-step voltage protocol, a minimal change in the steady-state inactivation of INa was found in the presence of LCS.	Lacosamide	122-125	internexin neuronal intermediate filament protein alpha	Homo sapiens	89-92
24563546-12	2014	Furthermore, both hNav1.5-CW/F1760K mutant and batrachotoxin-activated hNav1.5 Na(+) channels became completely lacosamide resistant, indicating that the lacosamide receptor overlaps receptors for local anesthetics and batrachotoxin.	Lacosamide	112-122	sodium voltage-gated channel alpha subunit 5	Homo sapiens	18-25
24563546-12	2014	Furthermore, both hNav1.5-CW/F1760K mutant and batrachotoxin-activated hNav1.5 Na(+) channels became completely lacosamide resistant, indicating that the lacosamide receptor overlaps receptors for local anesthetics and batrachotoxin.	Lacosamide	112-122	sodium voltage-gated channel alpha subunit 5	Homo sapiens	71-78
24563546-13	2014	Our results together suggest that lacosamide targets the intermediate preopen and open states of hNav1.5 Na(+) channels.	Lacosamide	34-44	sodium voltage-gated channel alpha subunit 5	Homo sapiens	97-104
24563546-14	2014	Lacosamide may thus track closely the conformational changes at the hNav1.5-F1760 region along the activation pathway.	Lacosamide	0-10	sodium voltage-gated channel alpha subunit 5	Homo sapiens	68-75
24065921-0	2013	A thermosensitive mutation alters the effects of lacosamide on slow inactivation in neuronal voltage-gated sodium channels, NaV1.2.	Lacosamide	49-59	sodium voltage-gated channel alpha subunit 2	Homo sapiens	124-130
24065921-5	2013	We studied the effects of a physiologically relevant concentration of lacosamide on the biophysical properties of NaV1.2 channels associated with either WT-beta1 or the mutant C121W-beta1 subunit.	Lacosamide	70-80	sodium voltage-gated channel alpha subunit 2	Homo sapiens	114-120
24065921-7	2013	Lacosamide was more effective in NaV1.2 associated with the WT-beta1 than with C121W-beta1 at either temperature.	Lacosamide	0-10	neuron navigator 1	Homo sapiens	33-37
24065921-7	2013	Lacosamide was more effective in NaV1.2 associated with the WT-beta1 than with C121W-beta1 at either temperature.	Lacosamide	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	63-68
23016711-7	2012	Application of 100 mum CBZ or 300 mum LCM reduced the maximal I(NaP) conductance in both wild-type and control mice.	Lacosamide	38-41	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, zeta	Mus musculus	62-68
23551115-0	2013	Potential role for human P-glycoprotein in the transport of lacosamide.	Lacosamide	60-70	ATP binding cassette subfamily B member 1	Homo sapiens	25-39
23551115-4	2013	We investigated whether a new AED, lacosamide (LCM), is a substrate of human Pgp.	Lacosamide	35-45	ATP binding cassette subfamily B member 1	Homo sapiens	77-80
23551115-4	2013	We investigated whether a new AED, lacosamide (LCM), is a substrate of human Pgp.	Lacosamide	47-50	ATP binding cassette subfamily B member 1	Homo sapiens	77-80
23551115-7	2013	Caco-2 assays were used to determine the intrinsic permeability and efflux ratio of LCM as well as its potential to inhibit digoxin, a Pgp substrate.	Lacosamide	84-87	ATP binding cassette subfamily B member 1	Homo sapiens	135-138
23551115-8	2013	KEY FINDINGS: Lacosamide was transported by MDR1-transfected cells from basolateral to apical sides.	Lacosamide	14-24	ATP binding cassette subfamily B member 1	Homo sapiens	44-48
23229998-9	2013	Isolated currents from the NaV 1.8 channel subtype were only marginally changed by lacosamide.	Lacosamide	83-93	sodium voltage-gated channel alpha subunit 10	Homo sapiens	27-34
23531742-5	2013	In contrast, novel AEDs, such as lacosamide, stabilize the slow-inactivated state in neuronal Nav1.1 and Nav1.7 isoforms.	Lacosamide	33-43	sodium voltage-gated channel alpha subunit 1	Homo sapiens	94-100
23531742-5	2013	In contrast, novel AEDs, such as lacosamide, stabilize the slow-inactivated state in neuronal Nav1.1 and Nav1.7 isoforms.	Lacosamide	33-43	sodium voltage-gated channel alpha subunit 9	Homo sapiens	105-111
17360008-0	2007	Antihyperalgesic efficacy of lacosamide in a rat model for muscle pain induced by TNF.	Lacosamide	29-39	tumor necrosis factor	Rattus norvegicus	82-85
22433297-3	2012	Here, we tested this possibility using the novel anticonvulsant (R)-N-benzyl 2-acetamido-3-methoxypropionamide ((R)-lacosamide [LCM]), which acts on both voltage-gated sodium channels and collapsin response mediator protein 2 (CRMP2), an axonal growth/guidance protein.	Lacosamide	64-110	dihydropyrimidinase-like 2	Rattus norvegicus	188-225
22433297-3	2012	Here, we tested this possibility using the novel anticonvulsant (R)-N-benzyl 2-acetamido-3-methoxypropionamide ((R)-lacosamide [LCM]), which acts on both voltage-gated sodium channels and collapsin response mediator protein 2 (CRMP2), an axonal growth/guidance protein.	Lacosamide	64-110	dihydropyrimidinase-like 2	Rattus norvegicus	227-232
22433297-3	2012	Here, we tested this possibility using the novel anticonvulsant (R)-N-benzyl 2-acetamido-3-methoxypropionamide ((R)-lacosamide [LCM]), which acts on both voltage-gated sodium channels and collapsin response mediator protein 2 (CRMP2), an axonal growth/guidance protein.	Lacosamide	128-131	dihydropyrimidinase-like 2	Rattus norvegicus	188-225
22433297-3	2012	Here, we tested this possibility using the novel anticonvulsant (R)-N-benzyl 2-acetamido-3-methoxypropionamide ((R)-lacosamide [LCM]), which acts on both voltage-gated sodium channels and collapsin response mediator protein 2 (CRMP2), an axonal growth/guidance protein.	Lacosamide	128-131	dihydropyrimidinase-like 2	Rattus norvegicus	227-232
22433297-4	2012	LCM inhibited CRMP2-mediated neurite outgrowth, an effect phenocopied by CRMP2 knockdown.	Lacosamide	0-3	dihydropyrimidinase-like 2	Rattus norvegicus	14-19
22433297-4	2012	LCM inhibited CRMP2-mediated neurite outgrowth, an effect phenocopied by CRMP2 knockdown.	Lacosamide	0-3	dihydropyrimidinase-like 2	Rattus norvegicus	73-78
22850102-3	2012	The bioavailability of lacosamide is 100% and is unaffected by food intake; protein binding is low; it is metabolized by CYP2C19 into inactive O-desmethyl lacosamide.	Lacosamide	23-33	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	121-128
21692503-0	2011	Identification of a lacosamide binding protein using an affinity bait and chemical reporter strategy: 14-3-3 zeta.	Lacosamide	20-30	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta	Homo sapiens	102-113
21692503-5	2011	Substitution of lacosamide AB agent ((R)-5) for (R)-2 led to the identification of the 14-3-3 zeta adduction site (K120) by mass spectrometry.	Lacosamide	16-26	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta	Homo sapiens	87-98
21949591-1	2011	The novel anti-epileptic drug lacosamide targets two proteins - voltage-gated sodium channels and collapsin response mediator protein 2 (CRMP-2) - suggesting dual modes of action for lacosamide.	Lacosamide	30-40	dihydropyrimidinase-like 2	Rattus norvegicus	98-135
21949591-1	2011	The novel anti-epileptic drug lacosamide targets two proteins - voltage-gated sodium channels and collapsin response mediator protein 2 (CRMP-2) - suggesting dual modes of action for lacosamide.	Lacosamide	30-40	dihydropyrimidinase-like 2	Rattus norvegicus	137-143
21949591-1	2011	The novel anti-epileptic drug lacosamide targets two proteins - voltage-gated sodium channels and collapsin response mediator protein 2 (CRMP-2) - suggesting dual modes of action for lacosamide.	Lacosamide	183-193	dihydropyrimidinase-like 2	Rattus norvegicus	98-135
21949591-1	2011	The novel anti-epileptic drug lacosamide targets two proteins - voltage-gated sodium channels and collapsin response mediator protein 2 (CRMP-2) - suggesting dual modes of action for lacosamide.	Lacosamide	183-193	dihydropyrimidinase-like 2	Rattus norvegicus	137-143
20538611-0	2010	In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein-2 identifies a pocket important in modulating sodium channel slow inactivation.	Lacosamide	63-73	dihydropyrimidinase-like 2	Rattus norvegicus	91-128
18972867-3	2008	Lacosamide enhances slow inactivation of voltage-gated sodium channels and modulates the collapsin response mediator protein-2 (CRMP-2), a protein, which is part of neuronal signal transduction pathways and which is attributed to neuroprotection.	Lacosamide	0-10	dihydropyrimidinase like 2	Homo sapiens	89-126
18972867-3	2008	Lacosamide enhances slow inactivation of voltage-gated sodium channels and modulates the collapsin response mediator protein-2 (CRMP-2), a protein, which is part of neuronal signal transduction pathways and which is attributed to neuroprotection.	Lacosamide	0-10	dihydropyrimidinase like 2	Homo sapiens	128-134
18378801-7	2008	The estimated IC(50) values for inhibition by lacosamide of Na(v)1.7-, Na(v)1.3-, and Na(v)1.8-type channels following prolonged inactivation were 182, 415, and 16 microM, respectively.	Lacosamide	46-56	immunoglobulin lambda variable 2-23	Homo sapiens	60-68
18378801-7	2008	The estimated IC(50) values for inhibition by lacosamide of Na(v)1.7-, Na(v)1.3-, and Na(v)1.8-type channels following prolonged inactivation were 182, 415, and 16 microM, respectively.	Lacosamide	46-56	immunoglobulin lambda variable 2-11	Homo sapiens	71-79
18378801-7	2008	The estimated IC(50) values for inhibition by lacosamide of Na(v)1.7-, Na(v)1.3-, and Na(v)1.8-type channels following prolonged inactivation were 182, 415, and 16 microM, respectively.	Lacosamide	46-56	neuron navigator 1	Homo sapiens	60-66
18378801-8	2008	Na(v)1.7-, Na(v)1.3-, and Na(v)1.8-type channels in the resting state were 221-, 123-, and 257-fold less sensitive, respectively, to lacosamide than inactivated channels.	Lacosamide	133-143	immunoglobulin lambda variable 2-23	Homo sapiens	0-8
18378801-8	2008	Na(v)1.7-, Na(v)1.3-, and Na(v)1.8-type channels in the resting state were 221-, 123-, and 257-fold less sensitive, respectively, to lacosamide than inactivated channels.	Lacosamide	133-143	immunoglobulin lambda variable 2-11	Homo sapiens	11-19
18378801-8	2008	Na(v)1.7-, Na(v)1.3-, and Na(v)1.8-type channels in the resting state were 221-, 123-, and 257-fold less sensitive, respectively, to lacosamide than inactivated channels.	Lacosamide	133-143	sodium voltage-gated channel alpha subunit 10	Homo sapiens	26-34
23859801-4	2013	Lacosamide has a well-characterized and favorable pharmacokinetic profile, including a fast absorption rate, minimal or no interaction with cytochrome P-450 izoenzymes, and a low potential for drug-drug interactions.	Lacosamide	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	140-156
29135908-8	2017	CONCLUSIONS: The performance of the new ARK method on the Architect system is acceptable and may be used routinely to measure serum lacosamide concentration in the clinic although the nature of the bias has to be carefully addressed.	Lacosamide	132-142	AXL receptor tyrosine kinase	Homo sapiens	40-43
34992539-0	2021	Lacosamide Inhibition of NaV1.7 Channels Depends on its Interaction With the Voltage Sensor Domain and the Channel Pore.	Lacosamide	0-10	sodium voltage-gated channel alpha subunit 9	Homo sapiens	25-31
34902360-3	2022	Therefore, we aimed to study the LCM effects on glial viability, microglial activation, expression of gap-junctional (GJ) protein Cx43 as well as intercellular communication in an in vitro astrocyte-microglia co-culture model of inflammation.	Lacosamide	33-36	gap junction protein, alpha 1	Rattus norvegicus	130-134
34992539-3	2021	It has been reported that lacosamide"s effect on NaV1.5 is sensitive to a mutation in the local anesthetic binding site, and that it binds with slow kinetics to the fast-inactivated state of NaV1.7.	Lacosamide	26-36	sodium voltage-gated channel alpha subunit 5	Homo sapiens	49-55
34992539-3	2021	It has been reported that lacosamide"s effect on NaV1.5 is sensitive to a mutation in the local anesthetic binding site, and that it binds with slow kinetics to the fast-inactivated state of NaV1.7.	Lacosamide	26-36	sodium voltage-gated channel alpha subunit 9	Homo sapiens	191-197
34992539-4	2021	We recently showed that the NaV1.7-W1538R mutation in the voltage-sensing domain 4 completely abolishes NaV1.7 inhibition by clinically-achievable concentration of lacosamide.	Lacosamide	164-174	sodium voltage-gated channel alpha subunit 9	Homo sapiens	28-34
34992539-4	2021	We recently showed that the NaV1.7-W1538R mutation in the voltage-sensing domain 4 completely abolishes NaV1.7 inhibition by clinically-achievable concentration of lacosamide.	Lacosamide	164-174	sodium voltage-gated channel alpha subunit 9	Homo sapiens	104-110
34992539-7	2021	To elucidate the mechanism by which lacosamide exerts its effects, we used voltage-clamp recordings and show that lacosamide requires an intact local anesthetic binding site to inhibit NaV1.7 channels.	Lacosamide	36-46	sodium voltage-gated channel alpha subunit 9	Homo sapiens	185-191
34992539-7	2021	To elucidate the mechanism by which lacosamide exerts its effects, we used voltage-clamp recordings and show that lacosamide requires an intact local anesthetic binding site to inhibit NaV1.7 channels.	Lacosamide	114-124	sodium voltage-gated channel alpha subunit 9	Homo sapiens	185-191
34992539-9	2021	We also show that the naturally occurring arginine in NaV1.3 (NaV1.3-R1560), which corresponds to NaV1.7-W1538R, is not sufficient to explain the resistance of NaV1.3 to clinically-relevant concentrations of lacosamide.	Lacosamide	208-218	sodium voltage-gated channel alpha subunit 3	Homo sapiens	160-166
34992539-11	2021	Together, the W1538 residue and an intact local anesthetic site are required for lacosamide"s block of NaV1.7 at a clinically-achievable concentration.	Lacosamide	81-91	sodium voltage-gated channel alpha subunit 9	Homo sapiens	103-109
34265537-9	2021	There were significant increases in the mean PR interval (from 169.3 msec to 184.5 msec, P < 0.01) and decreases in the mean heart rate (from 91.7 to 86.9, P = 0.01) after IV loading of LCM.	Lacosamide	186-189	transmembrane protein 37	Homo sapiens	45-47
34831395-8	2021	(S)-lacosamide ((S)-LCM), a small molecule that binds to CRMP2, decreased its phosphorylation at Thr 509/514 and Ser 522 and rescued CRMP2"s interaction with Drp1 and Miro 2.	Lacosamide	0-14	dihydropyrimidinase-like 2	Mus musculus	133-138
34831395-8	2021	(S)-lacosamide ((S)-LCM), a small molecule that binds to CRMP2, decreased its phosphorylation at Thr 509/514 and Ser 522 and rescued CRMP2"s interaction with Drp1 and Miro 2.	Lacosamide	0-14	collapsin response mediator protein 1	Homo sapiens	158-162
34831395-8	2021	(S)-lacosamide ((S)-LCM), a small molecule that binds to CRMP2, decreased its phosphorylation at Thr 509/514 and Ser 522 and rescued CRMP2"s interaction with Drp1 and Miro 2.	Lacosamide	0-14	ras homolog family member T2	Homo sapiens	167-173
34831395-8	2021	(S)-lacosamide ((S)-LCM), a small molecule that binds to CRMP2, decreased its phosphorylation at Thr 509/514 and Ser 522 and rescued CRMP2"s interaction with Drp1 and Miro 2.	Lacosamide	0-14	dihydropyrimidinase-like 2	Mus musculus	57-62
34685760-5	2021	The CRMP2-binding small molecule (S)-lacosamide ((S)-LCM) prevented an OA-induced increase in CRMP2 phosphorylation at Thr509/514 and Ser522 but not at Thr555, and also failed to alleviate Drp1 phosphorylation.	Lacosamide	33-47	dihydropyrimidinase like 2	Homo sapiens	4-9
34685760-5	2021	The CRMP2-binding small molecule (S)-lacosamide ((S)-LCM) prevented an OA-induced increase in CRMP2 phosphorylation at Thr509/514 and Ser522 but not at Thr555, and also failed to alleviate Drp1 phosphorylation.	Lacosamide	33-47	dihydropyrimidinase like 2	Homo sapiens	94-99
34265537-10	2021	Older age was significantly associated with a higher magnitude of the PR interval difference between before and after IV loading of LCM.	Lacosamide	132-135	transmembrane protein 37	Homo sapiens	70-72
34265537-12	2021	Elderly patients or patients with underlying cardiac diseases were prone to exhibiting a more prolonged PR interval after IV loading of LCM.	Lacosamide	136-139	transmembrane protein 37	Homo sapiens	104-106
33890297-10	2021	Carbamazepine reduced SLC44A1 transcript levels, whereas lacosamide modestly decreased the expression of SLC44A2.	Lacosamide	57-67	solute carrier family 44 member 2	Homo sapiens	105-112
34074008-2	2021	The aim of this study was to determine the effects of C-11 on the protective action of various antiepileptic drugs (i.e., carbamazepine CBZ, lacosamide LCM, lamotrigine LTG, and valproate VPA) against maximal electroshock-induced seizures (MES) in mice, as well as its neuroprotective and physicochemical/pharmacokinetic properties.	Lacosamide	141-151	polymerase (RNA) III (DNA directed) polypeptide K	Mus musculus	54-58
34610620-2	2022	The study aimed to evaluate the impact of ABCB1 polymorphisms on lacosamide (LCM) serum concentrations in Uygur pediatric epileptic patients.	Lacosamide	65-75	ATP binding cassette subfamily B member 1	Homo sapiens	42-47
34610620-2	2022	The study aimed to evaluate the impact of ABCB1 polymorphisms on lacosamide (LCM) serum concentrations in Uygur pediatric epileptic patients.	Lacosamide	77-80	ATP binding cassette subfamily B member 1	Homo sapiens	42-47
34610620-9	2022	Significantly lower LCM serum concentrations were observed in ABCB1 C3435T CT and TT genotype carriers than those in the CC carriers (p = 0.008 and p = 0.002), and a significantly lower LCM CD value was observed in ABCB1 C3435T CT genotype carriers than that in the CC carriers (p = 0.042).	Lacosamide	20-23	ATP binding cassette subfamily B member 1	Homo sapiens	62-67
34610620-10	2022	CONCLUSION: ABCB1 G2677T/A and C3435T polymorphisms may affect LCM serum concentrations and treatment efficacy in Uygur pediatric patients with epilepsy, leading to drug resistance in pediatric patients.	Lacosamide	63-66	ATP binding cassette subfamily B member 1	Homo sapiens	12-17
34273089-0	2021	Myoclonic dystonia (DYT11) responsive to lacosamide: a case report.	Lacosamide	41-51	sarcoglycan epsilon	Homo sapiens	20-25
35334412-5	2022	As a novel anti-epilepsy drug, Lacosamide is able to impair CRMP2 mediated tubulin polymerization.	Lacosamide	31-41	dihydropyrimidinase like 2	Homo sapiens	60-65
34022522-11	2021	Lamotrigine did not alter gene expression, and lacosamide slightly elevated SLC3A2 levels (p < 0.05).	Lacosamide	47-57	solute carrier family 3 member 2	Homo sapiens	76-82
33599301-0	2021	Use of Real-World Data and Pharmacometric Modeling in Support of Lacosamide Dosing in Pediatric Patients Under Four Years of Age.	Lacosamide	65-75	renin binding protein	Homo sapiens	125-128
33599301-5	2021	Based on the developed population pharmacokinetic model, simulations were performed in virtual pediatric patients to explore age-associated dose requirements to match lacosamide exposure in patient groups of different age with the exposure achieved in children >=4 year of age with the weight-based dosing recommendations provided by the FDA.	Lacosamide	167-177	renin binding protein	Homo sapiens	125-128
33925082-7	2021	Lacosamide treatment after SE mitigated the increased levels of IL-1beta and TNF-alpha in the hippocampus and exerted strong neuroprotection both in the dorsal and ventral hippocampus, basolateral amygdala, and partially in the piriform cortex.	Lacosamide	0-10	interleukin 1 alpha	Rattus norvegicus	64-72
33925082-7	2021	Lacosamide treatment after SE mitigated the increased levels of IL-1beta and TNF-alpha in the hippocampus and exerted strong neuroprotection both in the dorsal and ventral hippocampus, basolateral amygdala, and partially in the piriform cortex.	Lacosamide	0-10	tumor necrosis factor	Rattus norvegicus	77-86
33169403-5	2021	RESULTS: The method was linear within 0.5 - 40, 2.5 - 80 and 2.5 - 40 mug mL-1 for LCM, MHD and LTG, respectively (r2 >= 0.998).	Lacosamide	83-86	L1 cell adhesion molecule	Mus musculus	74-78
33714548-14	2021	RESULTS: The immunoreactivity of both iNOS and eNOS (oxidative stress markers) were decreased with LCM treatment compared to trauma group.	Lacosamide	99-102	nitric oxide synthase 2	Rattus norvegicus	38-42
33714548-14	2021	RESULTS: The immunoreactivity of both iNOS and eNOS (oxidative stress markers) were decreased with LCM treatment compared to trauma group.	Lacosamide	99-102	nitric oxide synthase 3	Rattus norvegicus	47-51
33714548-16	2021	The treatments of low (56,17+-9,69) and high-dose LCM (43,91+-9,09) were decreased the distribution of HIF-1alpha compared to trauma group (P<0.01).	Lacosamide	50-53	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	103-113
33307160-8	2021	Lacosamide revealed to inhibit BCRP in all tested concentrations (2.5-75 microM), exhibiting a significant increase (p<0.001) of the intracellular accumulation of a BCRP substrate (Hoechst 33342) in MDCK-BCRP cells.	Lacosamide	0-10	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	31-35
33307160-8	2021	Lacosamide revealed to inhibit BCRP in all tested concentrations (2.5-75 microM), exhibiting a significant increase (p<0.001) of the intracellular accumulation of a BCRP substrate (Hoechst 33342) in MDCK-BCRP cells.	Lacosamide	0-10	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	165-169
32853658-6	2020	Besides, lacosamide has extremely slow binding rates (<400 M-1sec-1) to the fast but much faster binding rates (>3,000 M-1sec-1) to the slow inactivated Na+ channels.	Lacosamide	9-19	secretory blood group 1, pseudogene	Homo sapiens	62-67
32853658-6	2020	Besides, lacosamide has extremely slow binding rates (<400 M-1sec-1) to the fast but much faster binding rates (>3,000 M-1sec-1) to the slow inactivated Na+ channels.	Lacosamide	9-19	secretory blood group 1, pseudogene	Homo sapiens	122-127